Business Wire

PHARNEXT-SA

Del

Pharnext to Present Latest Scientific Data on its Two Lead Assets at Several International Scientific Conferences

Regulatory News:

Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.

The company will attend the following events:

European Academy of Neurology (EAN) congress
June 16-18, 2018 in Lisbon, Portugal

Two ePosters (oral communications)

#EPR1170  

A multicenter, double-blind, placebo-controlled, pivotal phase III study (PLEO-CMT) of a
fixed combination of baclofen, naltrexone and sorbitol (PXT3003) for Charcot-Marie-Tooth
Disease Type 1A (CMT1A).

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room   Session EPR122 / Screen B12
Date/Time   June 16, 2018, 13:30 - 14:15 CEST
#EPR1007  

Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination
of acamprosate and baclofen in Alzheimer's disease.

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room   Session EPR101 / Screen A1
Date/Time   June 16, 2018, 13:30 - 14:15 CEST

International Congress on Neuromuscular Diseases (ICNMD)
July 6-10, 2018 in Vienna, Austria

Two Posters

#545   Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors   T. Prukop et al.
Room   Mezzanine Floor Gallery and Foyers
Date/Time   July 8, 2018, 5:15pm - 6:30pm CEST
#728  

Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A
DRG co-cultures.

Authors   N. Cholet et al.
Room   Session Room 1
Date/Time   July 8, 2018, 5:15pm - 6:30pm CEST

Innovations and State of the Art In Dementia Research meeting (ISADR)
July 16-18, 2081 in Valencia, Spain

Two Oral Communications

   

Cmax-based synergistic therapeutic effect on cognitive disability in mild Alzheimer’s
disease after 36 weeks treatment with baclofen and acamprosate.

Presenter:   Prof Jacques Touchon, MD, PhD, Faculteì de Meìdecine de Montpellier, France
Date/Time   July 16, 2018, 11:35am - 11:55am CEST
    A potential tri-therapy for Alzheimer’s disease.
Presenter:   Dr Rodolphe Hajj, PhD, Chief Pharmacology Officer, Pharnext, France
Date/Time   July 16, 2018, 12:55pm - 1:15pm CEST

Peripheral Nerve Society (PNS) congress
July 22-25, 2018 in Baltimore, US

One Oral Communication

   

Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease
(CMT1A).

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Date/Time   July 23, 2018, 2.45pm - 3.00pm EST

Four Posters

#20   Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors   R. Hajj et al.
Session   Session 1
Date/Time   July 22, 2018
#45  

Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease
(CMT1A)

Authors   R. Goedkoop et al.
Session   Session 2
Date/Time   July 23, 2018
#85  

Synergy of baclofen, naltrexone and sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A
(CMT1A)

Authors   J. Laffaire et al
Session   Session 2
Date/Time   July 23, 2018
#1

Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A
DRG co-cultures

Authors R. Hajj et al.
Session Session 3
Date/Time July 24, 2018

Alzheimer's Association International Conference (AAIC)
July 22-26, 2018 in Chicago, US

Two Posters

#P1-061  

Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination
of acamprosate and baclofen in Alzheimer’s Disease

Authors   J-M Orgogozo et al
Session   Session P1-01 / Hall F1
Date/Time   July 22, 2018, 9:30am - 4:15pm EST
#P3-042  

PXT864 combination restores cognitive deficits of Alzheimer’s mice, even in animals with
advanced disease that lost responsiveness to donepezil.

Authors   A. Brureau et al.
Session   Session P3-02, Hall F1
Date/Time   July 24, 2018, 9:30am - 4:15pm EST

If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to contact@pharnext.com

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit http://www.pharnext.com/

Contact:

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
Ulysse Communication
Bruno Arabian, +33 (0)1 81 70 96 30
barabian@ulysse-communication.com
or
Media Relations (U.S.)
RooneyPartners
Kate L. Barrette, +1 212 223 0561
kbarrette@rooneyco.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com